Figure 7.

Flow cytometry analysis the tumor infiltrating immune cells on parent wild-type MDA-MB-435 and resistant MDA-MB-435R tumors. (A) Untreated or Abraxane-treated MDA-MB-435 wild-type tumor tissues were dissected into single-cell suspensions and assessed by flow cytometry with fixable viability dye eFluor780, FITC-labeled CD45, PE-labeled CD11b, and Percp.Cy5.5-labeled F4/80. (B) Untreated or Abraxane-treated resistant MDA-MB-435R tumor tissues were dissected into single-cell suspensions and assessed by flow cytometry with fixable viability dye eFluor780, FITC-labeled CD45, PE-labeled CD11b, and Percp.Cy5.5-labeled F4/80. (C) Quantity data of negative cell population with fixable viability dye eFluor780 channel showed that there was significantly increased cell death of wild-type MDA-MB-435 tumors treated with Abraxane compared with untreated tumors (* P < 0.05), but there were no differences in the cell death ratio in resistant MDA-MB-435R tumors between the Abraxane-treated and untreated groups. (D) Cell population quantity data of immunized cell infiltrated into tumor tissue showed that there were significantly higher numbers of CD45⁺ myeloid cells, CD11b⁺ leukocytes, and F4/80⁺ macrophages infiltrated into tumor tissue in the Abraxane-treated group than in the untreated group for wild-type MDA-MB-435 tumors (*** P < 0.001). However, there was a significantly lower populations of CD45⁺ myeloid cells and CD11b⁺ leukocytes in the Abraxane-treated group than in the untreated group for resistant MDA-MB-435R tumors (* P < 0.05), and there were no differences in F4/80⁺ macrophage of Abraxane-treated group compared with the untreated group for resistant MDA-MB-435R tumors. Moreover, there were significantly lower populations of CD45⁺ myeloid cells, CD11b⁺ leukocytes, and F4/80⁺ macrophages in Abraxane-treated resistant MDA-MB-435R tumors than in Abraxane-treated wild-type MDA-MB-435 tumors (### P < 0.001), (mean ± SD; n = 4/group).